Logo
x

Search category

Subscribe Now

Merck

Merck and Eisai to Present P-III Study (CLEAR) Results of Keytruda + Lenvima as 1L Treatment for Advanced Renal Cell Carcinoma at ASCO 2023

Merck and Eisai to Present P-III Study (CLEAR) Results of Keytruda + Lenvima as 1L Treatment for Advanced Renal Cell Carcinoma at...

  • May 26, 2023
Insights+: The US FDA New Drug Approvals in April 2023

Insights+: The US FDA New Drug Approvals in April 2023

  • May 17, 2023
Merck to Acquire Prometheus for ~$10.8B

Merck to Acquire Prometheus for ~$10.8B

  • April 17, 2023
Merck Presents P-III Trial (KEYNOTE-966) Results of Keytruda for Advanced or Unresectable Biliary Tract Cancer at AACR 2023 Published in The Lancet

Merck Presents P-III Trial (KEYNOTE-966) Results of Keytruda for Advanced or Unresectable Biliary Tract Cancer at AACR 2023 Publis...

  • April 17, 2023
Merck Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of Evobrutinib for Multiple Sclerosis

Merck Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of Evobrutinib for Multiple Sclerosis

  • April 13, 2023
Merck and Eisai Highlighted Update on P-III Trials (LEAP-003) and (LEAP-017) of Keytruda (pembrolizumab) + Lenvima (lenvatinib)

Merck and Eisai Highlighted Update on P-III Trials (LEAP-003) and (LEAP-017) of Keytruda (pembrolizumab) + Lenvima (lenvatinib)

  • April 10, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.